Instruction for use: Bromanilidediethylaminopropanic acidI want this, give me price
Latin name of substance Bromanilidediethylaminopropanic acid
Acidum bromaniliddiaethylaminopropanicum (genus. Acidi bromaniliddiaethylaminopropanici)
2'-Bromoanilide-3-diethylaminopropanoic acid hydrochloride
The nosological classification (ICD-10)
R52 Pain, not elsewhere classified: Pain syndrome of radicular origin; Pain syndrome of small and medium intensity of different genesis; Pain syndrome after orthopedic surgery; Pain syndrome in superficial pathological processes; Radicular pain in the background of osteochondrosis of the spine; Radicular pain syndrome; Pleural pain; Chronic pain
Z01.2 Dental Examination: Extirpation of the tooth; Anesthesia of mucous membranes; Stomatological intervention
Z01.8 Other specified special examination: Anesthesia of mucous membranes; Preoperative examination
Z40 Preventive Surgery: Inhalational Anesthesia; Intratracheal Intubation; Intubation of the trachea; Surface anesthesia in ophthalmology
Characteristics of the substance Bromanilide diethylaminopropanoic acid
White crystalline powder.
Pharmacological action - local anesthetic.
Reversibly blocks the potential-dependent sodium channels, prevents the generation of pulses in the endings of the sensory nerves and their conduction along nerve fibers. Suppresses the holding of both pain impulses and impulses of another modality. When ingested, the systemic blood flow exerts a depressing effect on the central nervous system. Moderately lowers blood pressure, more often in patients with concomitant diseases of the cardiovascular system.
The time of onset and duration of local anesthesia depend on the route of administration and dose and are respectively: with conductive anesthesia - 10-20 min and 1.5-2 h, with spinal cord - 6-10 min and 0.5-1.5 h , with epidural - 25-30 minutes and 1 hour, with infiltration several minutes and 1-1.5 hours.
It has an anti-inflammatory effect and shortens the epithelization time (when applied to mucous membranes).
Application of the substance Bromanilide diethylaminopropanoic acid
Local anesthesia for surgical interventions and diagnostic manipulations.
Injection. Infiltration anesthesia (hernia repair, appendectomy, correction of dislocations, fractures of bones, etc.), conductive anesthesia (including large nerves and nerve plexuses), epidural and spinal anesthesia.
Solution for external use. Surface (terminal) anesthesia of the mucous membranes: in otolaryngology (carrying out various manipulations in the nasal cavity and ear - probing, catheterization, removal of polyps, electrocoagulation of bleeding sites of the nasal mucosa, puncture of the maxillary sinuses), in stomatology (aphthous stomatitis, bladder, pulpitis ), urology (catheterization), proctology (rectal fissures, proctitis, anal itching, epithelial coccygeal passage, period after hemorrhoidectomy), fibrobroncho- and fibrogastroscopy, etc. In anes Theology: application to the intubation tubes before intubation of the trachea.
Hypersensitivity, sinus bradycardia, age of up to 14 years (solution for injection).
Side effects of the substance Bromanilide diethylaminopropanoic acid
Solution for injection: dizziness, general weakness, lowering blood pressure. Solution for external use: allergic reactions.
Strengthens the depressing effect on the central nervous system of other local anesthetics, anesthetics, hypnotics, sedatives, tranquilizers, narcotic analgesics. Epinephrine increases the duration and severity of the effect.
Symptoms: pale skin of the face and mucous membranes, dizziness, general weakness, nausea, vomiting, arrhythmia, lowering blood pressure, up to collapse, motor excitement, convulsions.
Treatment: cessation of administration, maintenance of adequate oxygenation, intravenous injection of short-acting anesthetics; in severe cases - detoxification and symptomatic therapy.
Routes of administration
Precautions for the substance Bromanilide diethylaminopropanoic acid
Use with caution in patients prone to allergic reactions. Against the background of renal and hepatic insufficiency, smaller doses should be used. When combined with epinephrine, one should consider the possibility of manifesting its cardiotropic effects (increased heart rate, etc.).